Vivid Genomics
PrivateLast Round
Accelerator
Oct 25, 2018
Total Funding Raised
$20,000
Company Overview
Vivid Genomics is a biotechnology company that develops diagnostic tests for neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Clinical Trials, Medical AI, Biotechnology, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivid Genomics Comparables
Compare Vivid Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ADmit Therapeutics | 83% | |
| Polaris Genomics | 77% | |
| C₂N Diagnostics | 77% | |
Vivid Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Oct 25, 2018 |
Vivid Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ad Astra Ventures | Accelerator |
| Six Dragonflies | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 25, 2018
$20K round led by Ad Astra Ventures.
Vivid Genomics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Vivid Genomics's valuation, stock price, and market status.